Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS)

European Journal of Clinical Investigation

Volumn 34, Issue 1, 2004, Pages 21-28

  Klerkx, A H E M ^a   De Grooth, G J ^a   Zwinderman, A H ^a   Jukema, J W ^b   Kuivenhoven, J A ^a   Kastelein, J J P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiography; Atherosclerosis; CETP; Drugs; Lipids; Lipoproteins

Indexed keywords

CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

CARRIER PROTEINS; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DOUBLE-BLIND METHOD; GENOTYPE; GLYCOPROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PRAVASTATIN; TRIGLYCERIDES;

EID: 1242314787     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2004.01281.x     Document Type: Article

References (27)

1. Pedersen TR. Pro and con: low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management. Am J Cardiol 2001;87:8B-12B.
2. Yamashita S, Hirano K, Sakai N, Matsuzawa Y. Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein. Biochim Biophys Acta 2000;1529:257-75.
3. Hirano K, Yamashita S, Matsuzawa Y. Pros and cons of inhibiting cholesteryl ester transfer protein. Curr Opin Lipidol 2000;11:589-96.
4. Jiang XC, Masucci-Magoulas L, Mar J, Lin M, Walsh A, Breslow JL et al. Down-regulation of mRNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesteryl ester transfer protein. Mechanism to explain accumulation of lipoprotein B particles. J Biol Chem 1993;268:27406-12.
5. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406:203-7.
6. Inazu A, Jiang XC, Haraki T, Yagi K, Kamon N, Koizumi J et al. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. J Clin Invest 1994;94:1872-82.
7. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002;105:2159-65.
8. Föger B, Ritsch A, Doblinger A, Wessels H, Patsch JR. Relationship of plasma cholesteryl ester transfer protein to HDL cholesterol. Studies in normotriglyceridemia and moderate hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1996;16:1430-6.
9. Marcel YL, McPherson R, Hogue M, Czarnecka H, Zawadzki Z, Weech PK et al. Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects. J Clin Invest 1990;85:10-7.
10. Zhuang Y, Wang J, Qiang H, Li Y, Lui X, Li L et al. Serum cholesteryl ester transfer protein concentrations in healthy Chinese subjects and cardio-cerebrovascular disease patients. Clin Chim Acta 2001;305:19-25.
11. Brites FD, Bonavita CD, De Geitere C, Cloes M, Delfly B, Yael MJ et al. Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels. Atherosclerosis 2000;152:181-92.
12. Riemens S, van Tol A, Sluiter W, Dullaart R. Elevated plasma cholesteryl ester transfer in NIDDM. relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 1998;140:71-9.
13. Boekholdt SM, Thompson JF. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res 2003;44:1080-93.
14. Blankenberg S, Rupprecht HJ, Bickel C, Jiang XC, Poirier O, Lackner KJ et al. Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease. J Am Coll Cardiol 2003;41:1983-9.
15. Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-40.
16. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998;338:86-93.
17. van Venrooij FV, Stolk RP, Banga JD, Sijmonsma TP, van Tol A, Erkelens DW et al. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care 2003;26:1216-23.
18. Kuivenhoven JA, de Knijff P, Boer JM, Smalheer HA, Botma GJ, Seidell JC et al. Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler Thromb Vasc Biol 1997;17:560-8.
19. Kark JD, Sinnreich R, Leitersdorf E, Friedlander Y, Shpitzen S, Luc G. Taq1B CETP polymorphism, plasma CETP, lipoproteins, apolipoproteins and sex differences in a Jewish population sample characterized by low HDL-cholesterol. Atherosclerosis 2000;151:509-18.
20. Goto A, Sasai K, Suzuki S, Fukutomi T, Ito S, Matsushita T et al. Cholesteryl ester transfer protein and atherosclerosis in Japanese subjects: a study based on coronary angiography. Atherosclerosis 2001;159:153-63.
21. Fumeron F, Betoulle D, Luc G, Behague I, Ricard S, Poirier O et al. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. J Clin Invest 1995;96:1664-71.
22. Ordovas JM, Cupples LA, Corella D, Otvos JD, Osgood D, Martinez A et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Anerioscler Thromb Vasc Biol 2000;20:1323-9.
23. Klerkx AHEM, Tanck MWT, Kastelein JJP, Molhuizen HOF, Jukema JW, Zwinderman AH et al. Haplotype analysis of the CETP gene: not TaqIB, but the closely linked - 629C - >A polymorphism and a novel promoter variant are independently associated with CETP concentration. Hum Mol Genet 2003;12:111-23.
24. Contacos C, Barter PJ, Vrga L, Sullivan DR. Cholesteryl ester transfer in hypercholesterolaemia. Fasting and postprandial studies with and without pravastatin. Atherosclerosis 1998;141:87-98.
25. Inazu A, Koizumi J, Kajinami K, Kiyohar T, Chichibu K, Mabuchi H. Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma. Atherosclerosis 1999;145:405-13.
26. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000;20:189-97.
27. Ahnadi CE, Berthezene F, Ponsin G. Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects. Atherosclerosis 1993;99:219-28.